Laurie Toich, Assistant Editor

A method that involves a drug and a beam of ultraviolet light can kill 95% of cancer cells.

Top news of the day from across the healthcare landscape.

Sandoz announced efforts to create biosimilars for oncology and immunology branded drugs.

Specific blood-born microRNAs mutate before the development of hepatocellular carcinoma.

Overall survival of lung cancer patients in trial increased by 73%.

Sandoz to create biosimilars for 5 popular branded drugs.

Liver cancer cells died when the AURKA-MYC interaction was inhibited.

The bill aims to stop branded drug manufacturers from delaying the introduction of generic drugs.

Cost-sharing and prior authorization could potentially prevent patients from receiving alcohol or opioid abuse treatment.

Ocrevus treats relapsing and primary progressive multiple sclerosis.

An antibody derived from the human immune system may kill cancer cells with less harm to patient.

Women are more likely to die following a cardiac arrest than men.

Top news of the day from across the healthcare landscape.

Highest risk factors for readmissions include having Medicare or Medicaid insurance.

While cancer spending contributes largely to medical spending, it only accounted for 6.3% of growth from 2000 to 2012.

Epclusa is the first drug approved to treat all 6 major genotypes of hepatitis C virus.

Epclusa showed up to 99% viral suppression after 12 weeks across major hepatitis C genotypes.

Patients who received relebactam in combination with imipenem/cilastatin had a favorable microbiological response of 95.5 to 98.6%.

From 2012 to 2013, 4.8 million adults reported opioid use disorder, but only 17% received treatment.

A new model finds that a scrunching motion is needed to package DNA into a capsid.

Chemotherapy has the potential to make cancer cells more susceptible to immunotherapy.

Some injection drug users with HIV and hepatitis C seem to have the same immune problems as the elderly.

Top news of the day from across the healthcare landscape.

Researchers explore which patients with non-small cell lung cancer are more likely to respond to the immunotherapy atezolizumab.

Heart failure-related apps that monitor symptoms fall short of expectations.

Some programs prevent 1.55 fewer deaths per 100,000 people.

Higher doses of radiation found as effective as lower dose radiation for breast cancer treatment.

Patients treated with stereotactic body radiation therapy seen to have an increased risk of non-cancer death.

Hexosamine biosynthetic pathway could lead to potential treatments for certain prostate cancers.

Children who inherit 2 mutated ALPK3 genes have a 25% increased chance of having cardiomyopathy.